https://www.selleckchem.com/pr....oducts/bozitinib.htm
78, 95% CI 1.11, 2.88, p = 0.02), and trials with multiple co-PIs than with one PI (RR = 1.78 (95% CI 1.18, 2.67), p = 0.01). Overall, women's representation as a PI increased by 3% annually (by year of registration, R = 0.61, p = 0.01). This increase was most evident in trials registered in multiple continents and Europe (both 4% annually). Women's representation as PIs in clinical trials has increased in the last decade. Trials funded by multiple sources outside of Asia have the highest proportion of PIs who are women. These trends